00103/Autism A Double Blind Randomized Placebo Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin

NCT02410902

A Double Blind Randomized Placebo Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin

Associated Conditions

Neurodevelopmental Disabilities

Principal Investigator

Sponsor

Curemark

This is a Phase III multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of CM-AT in pediatric patients with autism at all levels of fecal chymotrypsin.

This study is currently enrolling.